| Size | Price | |
|---|---|---|
| 1mg | ||
| 5mg | ||
| 10mg | ||
| Other Sizes |
| Targets |
Platelet-activating factor (PAF) receptor (antagonist); NF-κB signaling pathway.
|
|---|---|
| ln Vitro |
Aglafoline inhibits PAF (3.6 nM)-induced platelet aggregation with an IC50 of approximately 50 μM and inhibits [3H]PAF binding to washed rabbit platelets with an IC50 of 17.8 ± 2.6 μM. It exerts anti-inflammatory, antioxidant, and potential neuroprotective effects primarily by inhibiting inflammatory signaling pathways such as NF-κB and reducing oxidative stress.
|
| ln Vivo |
No specific in vivo efficacy data are available for Aglafoline beyond its characterization as an effective PAF antagonist in vitro and in vivo. As a PAF antagonist, it would be expected to reduce platelet aggregation and inflammation in animal models, but no published in vivo results are currently documented.
|
| Enzyme Assay |
The PAF receptor binding assay uses washed rabbit platelets or membranes expressing recombinant PAF receptor. Radiolabeled [3H]PAF (3.6 nM) is used as a tracer. Test compounds compete for binding, and IC50 values are determined from competition curves to establish binding affinity and antagonist potency.
|
| Cell Assay |
In cellular assays, washed rabbit platelets are treated with Aglafoline and stimulated with PAF (3.6 nM). Platelet aggregation and ATP release are measured using a platelet aggregometer and luciferin-luciferase assay, respectively. The compound's ability to inhibit PAF-induced responses is quantified to determine IC50 values.
|
| Animal Protocol |
No specific in vivo animal study protocols are documented for Aglafoline. General models of inflammation or thrombosis in rodents could be used, with the compound administered systemically, and platelet aggregation, inflammatory cytokine levels, and thrombus formation assessed.
|
| Additional Infomation |
Aglafolin is a heterocyclic compound with a structure based on a 2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopentano[d]furan skeleton, with hydroxyl groups at C-1 and C-8b, a methoxycarbonyl group at C-2, a phenyl group at C-3, a 4-methoxyphenyl group at C-3a, and a methoxy group at C-6 and C-8. It is a platelet aggregation inhibitor found in Aglaia elliptifolia and Aglaia odorata. It is both a metabolite and a platelet aggregation inhibitor. It is an organic heterocyclic compound existing as a methyl ester. Aglafolin has been reported in Aglaia formosana, Aglaia elliptifolia, and other organisms with relevant data.
|
| Molecular Formula |
C28H28O8
|
|---|---|
| Molecular Weight |
492.5171
|
| Exact Mass |
492.178
|
| CAS # |
143901-35-3
|
| Related CAS # |
Rocaglamide;84573-16-0
|
| PubChem CID |
393601
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
3.135
|
| tPSA |
103.68
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
36
|
| Complexity |
778
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
O1C2C([H])=C(C([H])=C(C=2[C@@]2([C@@]([H])([C@]([H])(C(=O)OC([H])([H])[H])[C@@]([H])(C3C([H])=C([H])C([H])=C([H])C=3[H])[C@]12C1C([H])=C([H])C(=C([H])C=1[H])OC([H])([H])[H])O[H])O[H])OC([H])([H])[H])OC([H])([H])[H]
|
| InChi Key |
VFTGDXPPYSWBSO-GWNOIRNCSA-N
|
| InChi Code |
InChI=1S/C28H28O8/c1-32-18-12-10-17(11-13-18)28-23(16-8-6-5-7-9-16)22(26(30)35-4)25(29)27(28,31)24-20(34-3)14-19(33-2)15-21(24)36-28/h5-15,22-23,25,29,31H,1-4H3/t22-,23-,25-,27+,28+/m1/s1
|
| Chemical Name |
methyl (1R,2R,3S,3aR,8bS)-1,8b-dihydroxy-6,8-dimethoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3-dihydro-1H-cyclopenta[b][1]benzofuran-2-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol : ~100 mg/mL (~203.04 mM)
DMSO : ~21.43 mg/mL (~43.51 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.08 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.08 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: ≥ 2.14 mg/mL (4.35 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.14 mg/mL (4.35 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.4 mg/mL clear DMSO stock solution to 900 μL corn oil and mix evenly. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0304 mL | 10.1519 mL | 20.3037 mL | |
| 5 mM | 0.4061 mL | 2.0304 mL | 4.0607 mL | |
| 10 mM | 0.2030 mL | 1.0152 mL | 2.0304 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.